Form 4: Belite Bio CSO Executes Planned ADS Sale
Statement of Changes in Beneficial Ownership
Chief Scientific Officer Nathan L. Mata sold 1,001 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.
Summary
- Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 1,001 American depositary shares (ADS) on April 16, 2026.
- The transactions were executed in multiple tranches at weighted average prices ranging from $158.2784 to $164.1233 per share.
- Following these transactions, the reporting person retains beneficial ownership of 14,666 ADS.
- The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents a small portion of the executive's total holdings.
Positives
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.
Negatives
- Insider selling, even when planned, reduces the direct equity stake held by a key executive.
Risks
- Continued reliance on Rule 10b5-1 plans for liquidity by key management personnel.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector, often used by executives for personal financial planning rather than as a signal of company performance.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale was executed via a pre-planned, systematic trading program.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 12/10/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 04/16/2026 | Date of the reported ADS sales. |
| 04/20/2026 | Date the Form 4 was signed and filed. |
Keywords
Belite Bio, BLTE, Insider Trading, Form 4, Biotech, Nathan L. Mata
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.